Compounding Chemotherapy Market to Reach USD $7.74 Billion by 2029 at 6% CAGR

Compounding Chemotherapy Global Market Report 2025

The Business Research Company's Compounding Chemotherapy Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, August 21, 2025 /EINPresswire.com/ -- "Get 30% Off All Global Market Reports With Code ONLINE30 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors

How Big Is The Compounding Chemotherapy Market In 2025?
The market for compounding chemotherapy has seen a robust growth in the past few years. The market size, which is predicted to be $5.74 billion in 2024, is expected to expand to $6.11 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%. Factors behind the historical growth include an increased prevalence of cancer, greater uptake of hospital pharmacies, a surge in usage of antineoplastic agents, a heightened emphasis on dosage specific to patients, and the expanding influence of oncology-specialized clinics.

The market for compounding chemotherapy is predicted to witness rapid growth in the coming years, with projections to hit $7.74 billion by 2029, expanding at a compound annual growth rate (CAGR) of 6.1%. Several factors are contributing to this growth during the forecasted period, including an increased emphasis on precision medicine, a growing demand for oral and injectable chemotherapy compounds, the heightened use of hormonal and biological agents in oncology, a renewed focus on minimizing drug waste, and a surge in demand for targeted cancer treatments. Major trends forecasted for this period involve the adoption of technology in automated compounding devices, the development of individualized chemotherapy dosing protocols, the creation of mobile applications to aid in chemotherapy workflow, the incorporation of electronic health records (EHRs) into compounding systems, and the integration of barcode verification into compounding procedures.

Download a free sample of the compounding chemotherapy market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25724&type=smp

What Are The Key Driving Factors For The Growth Of The Compounding Chemotherapy Market?
The escalating occurrence of cancer cases is predicted to spur the expansion of the compounding chemotherapy market in the future. Cancer is a collection of diseases defined by unregulated growth and dissemination of unusual cells within the body. The surge in cancer cases can be mainly attributed to unhealthy lifestyles including poor eating habits, physical inactivity, smoking, high alcohol intake, and lengthy exposure to environmental contaminants, significantly increasing the chances of contracting different forms of cancer. Compounding chemotherapy aids in the treatment of cancer by offering custom-made medication concoctions adjusted to the specific needs of each patient, thereby enhancing effectiveness and reducing adverse effects. For example, the Australian Institute of Health and Welfare, a government agency based in Australia, reported in July 2024, that the number of diagnosed cancer cases in Australia in 2022 was 160,570, showing a rise of 3,789 cases in comparison to 156,781 in 2021. Consequently, the escalating occurrence of cancer cases facilitates the expansion of the compounding chemotherapy market.

Who Are The Key Players In The Compounding Chemotherapy Industry?
Major players in the Compounding Chemotherapy Global Market Report 2025 include:
• Baxter International Inc.
• Fresenius Kabi AG
• Grifols S.A.
• Option Care Health Inc.
• ICU Medical Inc.
• Dedalus S.p.A.
• Fagron NV
• BioScrip Inc.
• B. Braun Melsungen AG
• Medisca Pharmaceutique Inc.

What Are The Upcoming Trends Of Compounding Chemotherapy Market In The Globe?
Leading enterprises in the compounding chemotherapy sector are now prioritizing the development of groundbreaking solutions, such as robotic chemotherapy automation systems, in an effort to augment precision, security, and productivity in the processing of personalized cancer therapies. These sophisticated devices are engineered to prepare personalized chemotherapy dosages with exactness and safety by automating the compounding process, thereby curtailing the potential for human error and risk of contamination. For example, in February 2024, the Israel-based health tech company, Simplivia Healthcare Ltd, introduced the Smart Compounders Advanced Systems designed to mechanize and simplify the production of cytotoxic (chemotherapy) drugs. The systems can cater to the compounding of cytostatics and antibodies with a rate of 20 to 40 preparations per hour and feature automatic gravimetric verification and documentation to ensure extreme accuracy. Moreover, they remarkably curtail the pharmacy staff's contact with dangerous substances and are constructed to blend smoothly into existing laminar airflow (LAF) cabinets or isolators without necessitating any alterations.

What Segments Are Covered In The Compounding Chemotherapy Market Report?
The compounding chemotherapy market covered in this report is segmented –
1) By Drug Type: Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs
2) By Route Of Administration: Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal
3) By Technology: With Robotic Arms, Without Robotic Arms
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By Compounding Setting: Hospital Compounding, Compounding Pharmacies, Specialty Clinics, Homecare Settings

Subsegments:
1) By Cytotoxic Drugs: Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, Topoisomerase Inhibitors
2) By Hormonal Agents: Estrogen Antagonists, Androgen Deprivation Therapy Agents, Aromatase Inhibitors, Progestins, Gonadotropin-Releasing Hormone Agonists
3) By Immunomodulatory Agents: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Interleukins, Cytokines, Immune System Activators
4) By Targeted Therapies: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Poly Polymerase Inhibitors
5) By Supportive Care Drugs: Antiemetics, Erythropoiesis-Stimulating Agents, Bone-Modifying Agents, Pain Management Drugs

View the full compounding chemotherapy market report:
https://www.thebusinessresearchcompany.com/report/compounding-chemotherapy-global-market-report

Which Region Is Expected To Lead The Compounding Chemotherapy Market By 2025?
In 2024, North America led the compounding chemotherapy market, but Asia-Pacific is anticipated to experience the most rapid growth in the outlook period. The Compounding Chemotherapy Global Market Report 2025 includes regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Reports Similar to the Global Compounding Chemotherapy Market 2025, By The Business Research Company

Chemotherapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chemotherapy-global-market-report

Oncology Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Chemotherapy At Home Services Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chemotherapy-at-home-services-global-market-report

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company"

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.